HSPB1 and glioma: Therefore, this study was undertaken to determine whether SPARC itself is a therapeutic target or therapy to suppress glioma cell survival, to determine whether HSP27 inhibition is a better therapeutic strategy to suppress SPARC-induced survival, and to determine whether SPARC or HSP27 inhibition sensitizes glioma cells to radiation treatment or TMZ chemotherapy.